-
公开(公告)号:US08299070B2
公开(公告)日:2012-10-30
申请号:US12954438
申请日:2010-11-24
申请人: Teruhiko Inoue , Tetsudo Kaya , Shinichi Kikuchi , Koji Matsumura , Ritsuki Masuo , Motoya Suzuki , Michihide Maekawa
发明人: Teruhiko Inoue , Tetsudo Kaya , Shinichi Kikuchi , Koji Matsumura , Ritsuki Masuo , Motoya Suzuki , Michihide Maekawa
IPC分类号: A61K31/5355 , A61K31/4523 , A61K31/416 , C07D413/14 , C07D211/00 , C07D231/56
CPC分类号: C07D403/04 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04
摘要: Provided is an agent for the treatment or prophylaxis of inflammatory diseases, allergic diseases, autoimmune diseases, transplant rejection or the like.A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein each symbol is as described in the specification.
摘要翻译: 提供了用于治疗或预防炎性疾病,过敏性疾病,自身免疫性疾病,移植排斥反应等的药剂。 由下式[I]表示的化合物或其药学上可接受的盐或其溶剂合物:其中每个符号如说明书中所述。
-
公开(公告)号:US6017919A
公开(公告)日:2000-01-25
申请号:US117879
申请日:1998-08-06
申请人: Takashi Inaba , Tetsudo Kaya , Hiroyuki Iwamura
发明人: Takashi Inaba , Tetsudo Kaya , Hiroyuki Iwamura
IPC分类号: C07C233/73 , C07C235/34 , C07C235/36 , C07C235/38 , C07C235/46 , C07C235/48 , C07C235/50 , C07C235/54 , C07C235/56 , C07C235/66 , C07C237/20 , C07C237/22 , C07C237/32 , C07C237/42 , C07C237/44 , C07C255/60 , C07C271/16 , C07C275/28 , C07C311/46 , C07C317/28 , C07C323/42 , C07C323/60 , C07C323/62 , C07D233/60 , C07D295/13 , C07D295/185 , C07D295/192 , A61K31/525 , C07D401/00 , C07D403/00 , C07D417/00
CPC分类号: C07D295/185 , C07C233/73 , C07C235/34 , C07C235/36 , C07C235/38 , C07C235/46 , C07C235/48 , C07C235/50 , C07C235/54 , C07C235/56 , C07C235/66 , C07C237/20 , C07C237/22 , C07C237/32 , C07C237/42 , C07C237/44 , C07C255/60 , C07C271/16 , C07C275/28 , C07C311/46 , C07C317/28 , C07C323/42 , C07C323/60 , C07C323/62 , C07D295/13 , C07D295/192 , C07C2101/02 , C07C2101/04 , C07C2101/14 , C07C2102/10
摘要: The compounds of the formula (I) ##STR1## wherein each symbol is as defined in the specification, pharmaceutically acceptable salts thereof and pharmaceutical use thereof. The Compound (I) and pharmaceutically acceptable salts thereof of the present invention selectively act on cannabinoid receptors, particularly peripheral receptors, cause less side effects on the central system, and have superior immunoregulating action, antiinflammatory action, antiallergic action and therapeutic effect on nephritis. Therefore, they are useful as cannabinoid receptor, particularly peripheral cannabinoid receptor activators and antagonists, immunoregulators, therapeutic agents for autoimmune diseases, antiinflammatory agents, antiallergic agents and therapeutic agents for nephritis.
摘要翻译: PCT No.PCT / JP97 / 00291 Sec。 371日期1998年8月6日 102(e)1998年8月6日PCT PCT 1997年2月6日提交PCT公布。 出版物WO97 / 29079 日期1997年8月14日式(I)化合物其中每个符号如本说明书中所定义,其药学上可接受的盐和药物用途。 本发明的化合物(I)及其药学上可接受的盐选择性地作用于大麻素受体,特别是外周受体,对中枢系统产生较少的副作用,并具有优异的免疫调节作用,抗炎作用,抗过敏作用和对肾炎的治疗作用。 因此,它们可用作大麻素受体,特别是外周大麻素受体激活剂和拮抗剂,免疫调节剂,用于自身免疫疾病的治疗剂,抗炎剂,抗过敏剂和肾炎治疗剂。
-
公开(公告)号:US06806276B2
公开(公告)日:2004-10-19
申请号:US10245861
申请日:2002-09-16
申请人: Takashi Inaba , Tetsudo Kaya , Hiroyuki Iwamura
发明人: Takashi Inaba , Tetsudo Kaya , Hiroyuki Iwamura
IPC分类号: A61K3147
CPC分类号: C07D215/227 , C07D215/54 , C07D401/12 , C07D405/12
摘要: A 2-oxoquinoline compound or its pharmaceutically acceptable salt of general formula [I]: (wherein each symbol in the formula is as determined in the description), and its pharmaceutical use. The compound [I] of the present invention and its pharmaceutically acceptable salts selectively act on cannabinoid receptors, particularly on peripheral type cannabinoid receptors, and have fewer side effects on the central nervous system, having great immunosuppressive action, anti-inflammatory action or antiallergic action. Therefore, these compounds are useful as cannabinoid receptors (particularly peripheral type cannabinoid receptors) modulator, immunosuppressants, anti-inflammatory agents, and antiallergic agents.
摘要翻译: 2-氧代喹啉化合物或其通式[I]的药学上可接受的盐:其中式中的每个符号如说明书中所确定)及其药物用途。 本发明的化合物[I]及其药学上可接受的盐选择性地作用于大麻素受体,特别是对外周型大麻素受体,对中枢神经系统具有较少的副作用,具有很大的免疫抑制作用,抗炎作用或抗过敏作用 。 因此,这些化合物可用作大麻素受体(特别是外周型大麻素受体)调节剂,免疫抑制剂,抗炎剂和抗过敏剂。
-
公开(公告)号:US06509352B1
公开(公告)日:2003-01-21
申请号:US09869895
申请日:2001-08-29
申请人: Takashi Inaba , Tetsudo Kaya , Hiroyuki Iwamura
发明人: Takashi Inaba , Tetsudo Kaya , Hiroyuki Iwamura
IPC分类号: A61K3147
CPC分类号: C07D215/227 , C07D215/54 , C07D401/12 , C07D405/12
摘要: A 2-oxoquinoline compound or its pharmaceutically acceptable salt of general formula [I]: (wherein each symbol in the formula is as determined in the description), and its pharmaceutical use. The compound [I] of the present invention and its pharmaceutically acceptable salts selectively act on cannabinoid receptors, particularly on peripheral type cannabinoid receptors, and have fewer side effects on the central nervous system, having great immunosuppressive action, anti-inflammatory action or antiallergic action. Therefore, these compounds are useful as cannabinoid receptors (particularly peripheral type cannabinoid receptors) modulator, immunosuppressants, anti-inflammatory agents, and antiallergic agents.
摘要翻译: 2-氧代喹啉化合物或其通式[I]的药学上可接受的盐:其中式中的每个符号如说明书中所确定)及其药物用途。 本发明的化合物[I]及其药学上可接受的盐选择性地作用于大麻素受体,特别是对外周型大麻素受体,对中枢神经系统具有较少的副作用,具有很大的免疫抑制作用,抗炎作用或抗过敏作用 。 因此,这些化合物可用作大麻素受体(特别是外周型大麻素受体)调节剂,免疫抑制剂,抗炎剂和抗过敏剂。
-
公开(公告)号:US20110306599A1
公开(公告)日:2011-12-15
申请号:US12954438
申请日:2010-11-24
申请人: Teruhiko INOUE , Tetsudo KAYA , Shinichi KIKUCHI , Koji MATSUMURA , Ritsuki MASUO , Motoya SUZUKI , Michihide MAEKAWA
发明人: Teruhiko INOUE , Tetsudo KAYA , Shinichi KIKUCHI , Koji MATSUMURA , Ritsuki MASUO , Motoya SUZUKI , Michihide MAEKAWA
IPC分类号: A61K31/55 , A61K31/416 , C07D413/14 , A61K31/5377 , C07D401/14 , A61K31/454 , C07D403/14 , A61K31/496 , A61K31/422 , C07D417/14 , A61K31/427 , A61K31/433 , C07D471/04 , A61K31/437 , A61P29/00 , A61P19/02 , A61P37/08 , A61P37/06 , C07D231/56
CPC分类号: C07D403/04 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04
摘要: Provided is an agent for the treatment or prophylaxis of inflammatory diseases, allergic diseases, autoimmune diseases, transplant rejection or the like.A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein each symbol is as described in the specification.
摘要翻译: 提供了用于治疗或预防炎性疾病,过敏性疾病,自身免疫性疾病,移植排斥反应等的药剂。 由下式[I]表示的化合物或其药学上可接受的盐或其溶剂合物:其中每个符号如说明书中所述。
-
-
-
-